Author Index—2003

Note: (ab) represents abstract

A

Adelson, AJ, 1522(ab)
Aikawa, S, 1607(ab), 1615(ab)
Al-Enizi, E, 33
Alexander, LM, 1646(ab)
Allen, TR, 1527(ab)
Allison, J, 210
Almo, K, 1524(ab)
Alonso, O, 1537(ab)
Anastas, SM, 1538(ab)
Aparicio, EE, 216
Armbrust-Heinrich, H, 1634(ab)
Arroyo, AJ, 18, 1527(ab), 1541(ab)

B

Backfrieder, W, 1635(ab)
Bai, J, 1610(ab)
Baker, MK, 1542(ab)
Balan, A, 76
Balan, KK, 25, 76
Ballani, N, 1636(ab)
Ban, S, 1607(ab), 1615(ab)
Barondess, P, 1524(ab)
Barroga, DE, 1643(ab)
Bartenstein, P, 1634(ab)
Bass, CS, 1525(ab)
Bauman, TM, 1521(ab)
Becker, LM, 1529(ab)
Bednargzyk, EB, 1623(ab)
Bellard, S, 1648(ab)
Benkner, S, 1635(ab)
Beretta, M, 1537(ab)
Beyder, DD, 1623(ab)
Blefari, C, 37
Boellaard, R, 206
Brunken, RC, 1601(ab)
Brunken, RT, 1528(ab)
Buchholz, HG, 1634(ab)
Bull, MP, 1649(ab)
Bulling, S, 27
Bultynck, E, 72
Burney, R, 1529(ab)
Burney, RJ, 1533(ab), 1534(ab)
Burney, RL, 1643(ab)
Bybel, B, 1528(ab), 1601(ab)

C

Cai, W, 1610(ab)
Cao, Z, 210
Cerfolio, RJ, 1525(ab)
Chen, JC, 1606(ab)
Chen, K, 1610(ab)
Cheng, DW, 1603(ab)
Cheon, JH, 1630(ab)
Cheong, YY, 1630(ab)
Choo, HJ, 1621(ab)
Chou, YT, 1606(ab)
Choudhary, AK, 25, 76
Chung, JK, 1621(ab), 1637(ab)
Clarke, MK, 1636(ab)
Collier, BD, 33, 149
Collins, J, 165
Collins, JA, 170
Collins, PJ, 37
Conner, WT, 1522(ab)
Corley, JH, 210
Cuklanz, EJ, 42, 93, 176, 232
Custodio, JI, 1611(ab)
Cutrera, AM, 1643(ab)
Cutrera, P, 1521(ab)
Cutrera, PF, 1633(ab), 1643(ab), 1645(ab)

D

D'Agnolo, A, 1524(ab)
Dansereau, RN, 161
Dawadi, BR, 41
de Los Angeles, E, 1622(ab)
Decorah, MA, 1604(ab)
DeLano, DA, 1529(ab)
Demidov, VV, 1644(ab)
Dermawan, IS, 1641(ab)
Derose, CG, 1642(ab)
Deutsch, G, 1532(ab)
Díaz, MP, 216
Díaz, RR, 216
DiFilippo, F, 1601(ab)
Dobbeleir, AA, 1613(ab)
Dunnwald, LK, 1542(ab)

E

Eberl, S, 1610(ab)
Ebrahim, AK, 81
Elsaid, M, 1605(ab)
Elsamaloty, HM, 1541(ab)
Engelbrecht, G, 1635(ab)
Erwin, WD, 1539(ab)

F

Faraj, K, 25
Feng, D, 1610(ab)
Fig, LM, 56
Fink-Bennett, DM, 61
Forster, M, 1635(ab)
Forte, K, 1638(ab)
Fournelle, MM, 1629(ab)
Franssen, EJF, 206
French, W, 1622(ab), 1628(ab)
Fukuchi, K, 1608(ab)
Full, RT, 1528(ab)

G

Gabbie, H, 1524(ab)
Giannas, C, 1533(ab), 1534(ab)
Gordon, L, 56
Gordon, LI, 1643(ab)
Grahneis, J, 1540(ab)
Gregory, M, 1603(ab)
Greuter, HNJM, 206
Grey, C, 1628(ab)
Gropler, RJ, 1529(ab)
Gross, K, 165, 79
Grow, KS, 1604(ab)
Guarasci, DT, 1624(ab)

H

Hackett, MT, 170, 1522(ab)
Haddon, ED, 1645(ab)
Haegele, S, 1634(ab)
Halama, J, 1530(ab)
Ham, HR, 72
Hamblen, SM, 3
Hambye, AS, 1613(ab)
Hammerlund, LA, 1639(ab), 1641(ab)
Hans, HK, 1626(ab)
Hansen, JA, 1542(ab)
Harkness, B, 1, 59, 147, 189
Hartnett, SD, 1542(ab)
Hayashida, K, 1608(ab)
He, Y, 1644(ab)
Henkin, RE, 1530(ab)
Herrero, P, 1529(ab)
Higashino, H, 1616(ab)
Hirayama, A, 1535(ab)
Hoehnemann, S, 1634(ab)
Hoeper, TK, 1640(ab)
Hoffmann, K, 1540(ab)
Hommoud, S, 1605(ab)
Hooper, TJ, 1640(ab)
Hoshino, H, 1607(ab), 1615(ab)
Hsieh, JF, 1606(ab)
Hughes, DK, 196
Hwang, JJ, 1606(ab)

I

Ichise, M, 157
Innis, RB, 157
Ishida, Y, 1608(ab)
Ishikawa, H, 1625(ab)
Itoh, M, 1535(ab)
Iwase, M, 1535(ab)

J

Jang, JC, 1630(ab)
Jaskowiak, CJ, 1604(ab)
Joas, NM, 1649(ab)
John, P, 1635(ab)
Johnson, AC, 1633(ab)
Jones, JM, 1526(ab)
Jordan, KR, 1601(ab)

K

Karam, M, 161
Karavanov, A, 1644(ab)
Kasner, DL, 21
Katafuchi, T, 1608(ab)
Kawahara, K, 1535(ab)
Kawai, H, 1625(ab)
Kazem, N, 33
Keech, F, 2, 60
Khandekar, SP, 1601(ab)
Kiat, H, 1524(ab)
Kiefer, V, 165
Kim, KS, 1630(ab)
Kim, MK, 1621(ab), 1637(ab)
Kinda, A, 1616(ab)
Kíratlí, PÖ, 74
Kobayashi, T, 1535(ab)
Kohrs, CJ, 1538(ab)
Kotsyubko, O, 1622(ab), 1628(ab)
Krul, AC, 1626(ab)
Kubo, N, 1607(ab), 1615(ab)
Kulkarni, KP, 1636(ab)
Kusuhara, T, 1609(ab)

L

LaForest, R, 1529(ab)
Lambert, CA, 1641(ab)
Lamerton, PE, 1523(ab)
Lammertsma, AA, 206
Lee, BH, 1637(ab)
Lee, WH, 1627(ab)
Lee, YJ, 1621(ab), 1637(ab)

Leresche, M, 27
Liow, J-S, 157
Liu, HG, 1525(ab), 1532(ab)
Liu, K, 1629(ab), 1640(ab), 1649(ab)
Liu, RS, 1614(ab)
Loutfi, I, 149, 81, 1611(ab)
Lowe, VJ, 3

M

Mahone, TJ, 1525(ab)
Mankoff, DA, 1542(ab)
Mannes, F, 72
Manson, LL, 1629(ab)
Masui, S, 1625(ab)
Masumura, O, 1607(ab), 1615(ab)
Mathew, M, 33
Matsumoto, K, 1602(ab)
McAndrew, PF, 1524(ab)
Mcdonald, NA, 1633(ab)
McDonald, NA, 1638(ab), 1639(ab), 1641(ab), 1642(ab), 1643(ab), 1645(ab)
McGough, JJ, 1544(ab)
McGregor, AC, 1522(ab)
McNall, MA, 1604(ab)
Mehlburg, L, 148, 190
Miguchi, H, 1616(ab)
Mihalache, I, 1622(ab)
Mihalache, II, 1531(ab)
Minkus, KD, 18
Miranda, JT, 1627(ab)
Mishkin, F, 1622(ab), 1628(ab), 1631(ab), 1648(ab)
Mishkin, FS, 1531(ab), 1544(ab)
Miyazaki, Y, 1625(ab)
Mochizuki, T, 1616(ab)
Mohammed, AM, 149
Monden, T, 1609(ab)
Montalbano, GP, 1639(ab)
Moon, WY, 1630(ab)
Morano, GN, 191
Mountz, JM, 1525(ab), 1532(ab)
Murase, K, 1608(ab), 1616(ab)
Murphy, K, 230
Mut, F, 1537(ab)
Myers, DL, 1541(ab)

N

Núñez, M, 1537(ab)
Nair, MK, 81, 1611(ab)
Nam, KP, 1630(ab)
Nelp, WB, 1542(ab)
Neumann, RD, 1644(ab)
Nishimura, Y, 1608(ab)
Nishio, M, 1535(ab)
Nishiyama, Y, 1609(ab)

O

Oh, SJ, 1630(ab)
Ohkawa, M, 1609(ab)
Ohnishi, H, 1602(ab)
Ojha, BC, 1525(ab)
Oka, H, 1608(ab)
Osman, MM, 1538(ab)
Owunwanne, A, 33

P

Palestro, CJ, 1543(ab)
Panyutin, IG, 1644(ab)
Park, JH, 1637(ab)
Park, YH, 1621(ab)
Patel, YP, 18, 1527(ab), 1541(ab)
Pearce, JH, 1526(ab)
Perry, DJ, 1533(ab), 1534(ab)
Pham, HL, 1531(ab), 1622(ab), 1628(ab), 1631(ab)
Phillips, EH, 1524(ab)
Piepsz, A, 72
Poppe, F, 173(le)
Prekeges, JL, 11, 86, 173(le)
Pugliese, PV, 1543(ab)

R

Rösch, F, 1634(ab)
Raman, A, 1532(ab)
Ramkumar, S, 25
Rapae, T, 1622(ab)
Rizo, OD, 216
Rodríguez, CH, 216

S

Sajdak, RA, 1530(ab)
Salancı, BV, 74
Sayed, MG, 1636(ab)
Schmitt, MA, 1533(ab), 1534(ab)
Schoenstra, T, 165
Schreckenberger, M, 1634(ab)
Schwaiger, M, 1540(ab)
Schwarz, SW, 1529(ab)
Sebastian, MV, 1527(ab)
Seibyl, JP, 191
Semaan, HB, 18, 1527(ab), 1541(ab)
Senda, M, 1602(ab)
Sheehan, RM, 1603(ab)
Shehab, F, 1605(ab)
Shih, W-J, 79, 165
Shin, JH, 1621(ab), 1637(ab)
Siessmeier, T, 1634(ab)
Smith, HS, 161
Soheili, A, 1647(ab)
Sperrazza, JS, 1624(ab)
Spies, SM, 1521(ab), 1633(ab), 1638(ab), 1641(ab), 1642(ab), 1643(ab)
Spies, WG, 1639(ab)
Spieth, ME, 21, 163, 1629(ab), 1640(ab), 1649(ab)
Stachowiak, AM, 1539(ab)
Stacy, SG, 1522(ab)
Stringer, S, 1533(ab), 1534(ab)
Stubbs, RS, 1523(ab)

T

Takahashi, A, 1625(ab)
Takahashi, Y, 1616(ab)
Takase, H, 1625(ab)
Tamai, S, 1535(ab)
Tamak, T, 1535(ab)
Thomas, CR, 1544(ab)
Thomas, K, 61
Tomas, MB, 1543(ab)
Toriyama, T, 1625(ab)
Toyama, H, 157
Tran, TN, 1631(ab)
Tsopelas, C, 37

V

Valley, J-F, 27
Van Der Mauten, L, 72
van Lingen, A, 206
Van Roijen, N, 72
Vervaet, AM, 1613(ab)
Vines, DC, 157
Vogt, T, 1634(ab)
Voll, BM, 1641(ab)

W

Wang, JK, 1614(ab)
Wastiel, C, 27
Waterstram-Rich, K, 92, 174
Waxman, AD, 1524(ab)
Wells, RG, 1647(ab)
Wen, L, 1610(ab)
Wendt, RE, 1539(ab)
Wierzbinski, B, 165
Wierzbinski, RS, 170
Williams, CM, 1524(ab)
Williams, M, 1622(ab), 1628(ab)
Wishart, G, 76
Wojtylak, PF, 1612(ab)
Wu, LC, 1614(ab)

Y

Yabuno, T, 1607(ab), 1615(ab)
Yamaguchi, K, 1535(ab)
Yamamoto, Y, 1609(ab)
Yamashita, E, 1535(ab)
Yasuda, S, 1609(ab)
Ye, XX, 1606(ab)
Yester, MV, 1525(ab)
Yokoi, T, 1602(ab)
Yost, PE, 1538(ab)

Z

Zimmer, AM, 1521(ab), 1633(ab), 1638(ab), 1639(ab), 1641(ab), 1642(ab), 1643(ab)
Zubal, G, 1603(ab)

Subject Index—2003

Note: (ab) represents abstract

A

Activity concentration, FDG, direct calibration and standard solution methods of measurement, 206
Adverse reactions, ^{99m}Tc MDP, 76
Artifacts
bone scintigraphy, electronic off-peak status of one head of gamma camera, 165
decubitus SPECT, role in myocardial perfusion imaging, 1531(ab)
PET/CT, technologist introduction to, 1604(ab)
Attenuation correction
brain SPECT, improving acquisition and processing of data, 191
PET/CT artifacts, 1604(ab)
segmented, transmission time to PET counts and, 1536(ab)

B

Basal ganglia, uptake of ^{123}I altropane, in attention deficit hyperactivity disorder, 1544(ab)
Blood samples, measurement of FDG concentrations in, 206
Bone scintigraphy
asymmetrical energy window of ^{99m}Tc, quality and, 1605(ab)
gamma camera, electronic off-peak status of one head, artifacts and, 165
^{99m}Tc MDP
reduced hemithoracic uptake, 24
severe systemic reactions to, 76
nonosseous abnormalities in, 149
uptake in thoracic vertebrae, midcourse of lung cancer irradiation, 79
Brain SPECT
improving acquisition and processing of data, 191
quantitative
dual-head camera performance effects, 1537(ab)
scatter correction using a striatal phantom, 157
statistical parametric imaging, with orthostatic hypotension, 1609(ab)
Breast cancer
nonosseous abnormalities in bone scintigraphy, 149
prone imaging protocol for, FDG PET, 1524(ab)

C

Cardiac imaging, ^{82}Rb myocardial perfusion, 3D acquisition and processing, 1530(ab)
Cerebral blood flow, improving acquisition and processing of data, brain SPECT, 191
Collimation, collimators, cardio high-sensitivity
left ventricular function, 1607(ab)
myocardial SPECT, ejection fraction, 1615(ab)
Colorectal cancer, selective internal radiation therapy, MAA scanning prior to, 1523(ab)
Contamination
radioactive, internal bacteria filter of Xenon ventilation system, 170
radioisotope urinary, 21
Cost-effectiveness, whole-body FDG PET, malignancy staging, routine inclusion of brain in, 1532(ab)
Cost reduction, ^{99m}Tc MAG3 kit, storage conditions for, 74

D

Data analysis, evaluation of gastric emptying, 1601(ab)
Diaphragmatic leak, isotopic peritoneography for, accidental small bowel puncture, 163
Dopamine transporters, basal ganglion uptake, in attention deficit hyperactivity disorder, 1544(ab)
Dose calibration, for β-emitters, efficiency of, 27
Dosimetry
^{18}F, human and gamma camera issues, 210
FDG concentrations, measurement in blood samples, 206
^{99m}Tc MAG3 administered activity optimization, renography for adults, 216
quantitative whole-body imaging, 1539(ab)
^{90}Y zevalin, using a manual injector system, 1521(ab)

E

Editor's page, 1, 59, 147, 189
Exercise, pulmonary uptake of ^{99m}Tc sestamibi, smokers *vs.* nonsmokers, 1527(ab)

F

Filtered backprojection, improving acquisition and processing of data, brain SPECT, 191
Fluorine-18, protection issues, human and gamma camera issues, 210
Fluorine-18 FDG. *see* Fluorodeoxyglucose (FDG)
Fluorodeoxyglucose (FDG)
concentrations, measurement in blood samples, 206
muscle uptake, impact of low carbohydrate diet, 1612(ab)
PET
oncology patient preparation techniques, 3
probe breast imaging protocol for, 1524(ab)
residual activity, post-injection, 1538(ab)
whole-body PET, malignancy staging, routine inclusion of brain in, 1532
Fractioning, ^{99m}Tc MAG3 kit, 74

G

Gallium-67 citrate, colloid labeled leukocytes, 196
Gamma camera
dual-head, electronic off-peak status of one head, artifacts and, 165
^{18}F protection issues, 210
gantry-free, non-conventional design and flexibility, 1540(ab)
whole-body imaging, pitfalls in, 1539(ab)
Gastric emptying
establishing normal values for alternate meals, 1603(ab)
evaluation, time-saving method, 1601(ab)

H

Hepatobiliary excretion, ^{99m}Tc MAG3, in routine renography, 18
Hepatorenal dysfunction, systemic reactions to ^{99m}Tc MDP, 76

I

Image contrast, brain phantom, quantitative SPECT, 1537(ab)
Image coregistration, gated myocardial SPECT, CAG and, cost-effective method, 1608(ab)
Image management, nuclear medicine patient form, 24 h-a-day access to, 1613(ab)
Image quality, ^{99m}Tc MAG3 administered activity optimization, renography for adults, 216
Image reconstruction, commercial ML-EM software programs for, comparison, 1602(ab)
Indium-111 oxine, infection imaging with, 196
Infection imaging, nuclear medicine and, 196
Insulin, PET protocol for cardiac viability imaging, 1528(ab)
Intersocietal Commission for the Accreditation of Nuclear Medicine Laboratories (ICANL), site visit, 56
Iodine-125, radioactive seeds, pathology specimens containing, 1522(ab)
Iodine-131, oral administration by semiautomatic pipette, 161
Iodine-131 sodium, therapy, whole-body dosimetry for thyroid cancer, 1542(ab)

J

Joint Review Committee on Educational Programs in Nuclear Medicine (JRCNMT), proceedings, 42, 93, 176, 232

L

Lead shielding, ^{18}F, human and gamma camera issues, 210
Lung adenocarcinoma, irradiation, uptake by thoracic vertebrae in midcourse, 79
Lung cancer, staging, PET or PET/CT scanner, 1525(ab)

M

Message from the President, 2, 60, 148, 190
Multimodality imaging
PET/CT, NMT transition to, 1534(ab)
PET or PET/CT, FDG, lung cancer, 1525(ab)
Myocardial perfusion imaging, PET, blood-pool clearance and tomograph type effects, 1529(ab)
Myocardial SPECT
gamma camera, electronic off-peak status of one head, artifacts and, 165
gated
CAG and, coregistration between, 1608(ab)

Myocardial viability
cardio high-sensitivity collimator, ejection fraction, 1615(ab)
decubitus role, 1531(ab)
left ventricular function, high-sensitivity collimators in, 1607(ab)
^{99m}Tc tetrofosmin, early fasting and delayed post fatty meal imaging, 1611(ab)
PET protocol for, insulin use in, 1528(ab)

N

Non-Hodgkin's lymphoma, B-cell, ^{90}Y ibritumomab tiuxetan in treatment, 61
Nuclear medicine
information TV, patient services, 1614(ab)
pediatric studies, optimizing in a general hospital, 1543(ab)
Nuclear medicine technologists
performance and responsibility guidelines (revision 2003), 222
transition to PET/CT scanner, 1534(ab)
Nuclear Medicine Technologists Certification Board (NMTCB)
performance and responsibility guidelines (2003), 222
report, 41, 92, 174, 230
task analysis report, 86

O

Oncology, patient preparation for clinical FDG PET, 3
Ordered subsets expectation maximization (OSEM), number of SPECT projections in, 1616(ab)

P

Palliation, β-emitting radionuclides, dose calibrators for, 27
Parametric imaging, generalized linear squares algorithms for, dynamic SPECT, 1610(ab)
Parathyroid adenoma, dynamic data acquisition, ^{99m}Tc sestamibi, 1541(ab)
Patient preparation, clinical FDG PET, 3
Pediatric patients
^{99m}Tc DMSA renal scintigraphy, posterior oblique views, children, 72
nuclear imaging, general hospital, 1543(ab)
PET
FDG
oncology patient preparation techniques, 3
residual activity, post-injection, 1538(ab)
quality control, systematic approach for NMT, 1533(ab)
transmission time to counts, segmented attenuation correction, 1536(ab)
PET/CT scanner, transition to, 1534(ab)
Picture Archiving Computer System (PACS)
nuclear medicine information TV, 1614(ab)
nuclear medicine patient form, 24 h-a-day access, 1613(ab)
Pleural effusion
accidental small bowel puncture, patient positioning in, 163
malignant, nonosseous abnormalities in bone scintigraphy, 149
reduced hemithoracic uptake of ^{99m}Tc MDP and, bone scintigraphy, 24
Prostate cancer, radioactive seeds, pathology specimens containing, 1522(ab)

Q

Quality control
gamma camera, electronic off-peak status of one head, artifacts and, 165
PET, systematic approach for NMT, 1533(ab)
Quantitative analysis, ^{99m}Tc pertechnetate, salivary gland scintigraphy, 81

R

Radiation
effects of, nuclear medicine technologists, 11, 173(le)
monitoring, contamination, internal bacteria filter of Xenon ventilation system, 170
Radiation hormesis, regulations on radiation, 11, 173(le)
Radiation safety, staff, procedures for reduction of, 37
Radiation therapy
dose calibrators for β-emitters, efficiency of, 27
lung cancer, uptake by thoracic vertebrae in midcourse, 79
Radiobiology, regulations on radiation, 11, 173(le)
Radiochemicals
impurities, dextrose solutions, 33
purity, ^{99m}Tc tetrofosmin, various reconstitution parameters, 1526(ab)
Radioimmunotherapy, B-cell non-Hodgkin's lymphoma, 61
Radioisotopes, urinary contamination with, 21
Radiopharmaceuticals
β-emitters, dose calibrators for, 27
impurities, dextrose solutions, 33
procedures to reduce staff exposure, 37
Renal cell carcinoma, nonosseous abnormalities in bone scintigraphy, 149
Renal scintigraphy, ^{99m}Tc DMSA, posterior oblique views, children
Renography, ^{99m}Tc MAG3
administered activity optimization for adults, 216
hepatobiliary excretion of, 18
Rubidium-82, myocardial perfusion imaging
blood-pool clearance and tomograph type effects, 1529(ab)
3D acquisition and processing, 1530(ab)

S

Salivary gland, scintigraphy, 81
Scatter correction, striatal phantom for, quantitative brain SPECT, 157
Serotonin transporters, imaging agent, rabbit brain, 1606(ab)
Small bowel, accidental puncture, importance of patient positioning, 163
SPECT
dynamic, generalized linear squares algorithms for, 1610(ab)
image reconstruction, commercial ML-EM software programs for, 1602(ab)
serotonin transport as imaging agent, rabbit brain, 1606(ab)
Stress testing, ^{99m}Tc ECD SPECT, using statistical parametric mapping, 1609(ab)
Striatal phantom, for scatter correction, quantitative brain SPECT, 157
Swallowing difficulties, oral administration of ^{131}I, by semiautomatic pipette, 161

T

Technetium-99m, colloid labeled leukocytes, infection imaging with, 196
Technetium-99m dextrose, radiochemical impurities, 33
Technetium-99m DMSA, renal scintigraphy, posterior oblique views, children, 72
Technetium-99m HMPAO, infection imaging with, 196
Technetium-99m MAA, isotopic peritoneography, accidental small-bowel puncture, 163
Technetium-99m MAG3
administered activity optimization, renography for adults, 216
hepatobiliary excretion of, in routine renography, 18
kit, storage conditions for, 74
Technetium-99m MDP
bone scan, asymmetrical energy window of, 1605(ab)
bone scintigraphy, reduced hemithoracic uptake, 24
severe systemic reactions to, 76
Technetium-99m medronate, urinary contamination with, 21
Technetium-99m MIBI, dynamic data acquisition, parathyroid adenoma, 1541(ab)
Technetium-99m pertechnetate, salivary gland scintigraphy, 81
Technetium-99m sestamibi, lung uptake, during myocardial perfusion imaging, 1527(ab)
Technetium-99m sulfur colloid, radiolabeled meals, normal values for gastric emptying, 1603(ab)
Technetium-99m tetrofosmin
myocardial SPECT, early fasting and post fatty meal imaging, 1611(ab)
radiochemical purity of, air addition and, 1526(ab)
Technologist News, 57, 94, 185, 233
Thoracic spine, bone scintigraphy, uptake during cancer irradiation, 79
Thyroid cancer, ^{131}I therapy, whole-body dosimetry for, 1542(ab)
Tracer delivery, semiautomatic pipette, use in swallowing difficulties, 161
Transmission CT, SPECT projections, in OSEM reconstruction method, 1616(ab)
Tumor imaging, uptake of FDG, impact of low carbohydrate diet, 1612(ab)

U

Urine, contamination with radioisotopes, 21

X

Xenon-133, contamination, internal bacteria filter of Xenon ventilation system, 170

Y

Yttrium-90, microspheres, metastatic carcinoma, MAA scanning prior to, 1523(ab)
Yttrium-90 ibritumomab tiuxetan, treatment, B-cell non-Hodgkin's lymphoma, 61
Yttrium-90 zevalin, dosimetry, using a manual injector system, 1521(ab)

Z

Zevalin. *see* Yttrium-90 ibritumomab tiuxetan (zevalin)